Figure 1

Assay	Human CCR3	Monkey CCR3	Mouse CCR3	Rat CCR3	Canine CCR3
Cell line receptor binding Ki (nM)	3		124	1489	
Cell line Ca^{2+} influx IC_{50} (nM)	1			1155	
Cell line chemotaxis IC_{50} (nM)	23	25	485		
Eosinophil chemotaxis IC_{50} (nM)	65				
Eosinophil Ca^{2+} influx IC_{50} (nM)					
Eosinophil CCR3 internalization IC_{50} (nM)	27				
Eosinophil shape change IC_{50} (nM)	4	3			
Eosinophil whole blood shape change IC_{50} (nM)	31	2			53-30000

Figure 2



Screening
Treatment period (400 mg BI 144807 twice daily)
Follow-up period
V1
V2
V3
V4
V5
Eo T
FU V7
FU V8
-7 to -2 days
7±1 days
7±1 days
7±1 days
7±1 days
14±3 days
14±3 days

Figure 3



600
550
500
450
400
350
300
Mean (SEM) central retinal thickness (μm)
2
N=14
3
N=14
4
N=14
5
N=13
6
N=13
7
N=9
8
N=6
Visit

Figure 4





Table 14.3.2.1 Descriptive statistics over time for cecmacular leakage area (mm²) as assessed by FA - treated set (OC)

	Total					
	N	Mean	SD	Min	Median	Max
Absolute values (mm²)						
Baseline	13	6.7	6.6	1.0	4.5	21.5
Visit 4	13	4.9	4.6	0.3	3.7	13.7
Visit 6	11	4.9	4.7	1.0	3.7	12.3
Visit 8 ~ EOT	5	8.3	7.3	1.3	7.1	21.2
Change from baseline (mm²)						
Visit 4	12	-2.0	3.4	-11.1	-0.3	1.3
Visit 6	10	-0.7	1.4	-4.2	-0.6	1.2
Visit 8 ~ EOT	5	0.7	1.3	-0.8	0.3	2.7

Figure 5


BCVA
(changes from Baseline/letters)
10
9
8
7
6
5
4
3
2
1
0
baseline
WK1
WK2
WK3
WK4
treatment period
Maximal effect of anti-VEGF;>1 year treatment (Δ=6.7 letters)
anti-VEGF, IVT
Inv. Cmpd. (BCVA≥2 letters; n=8)
anti-VEGF; 1 month treatment (Δ=4.2 letters)
Inv. Cmpd. (all patients, n=14)
sham control